Dr Lenka Munoz

Lecturer
Pharmacology, School of Medical Sciences

D06 - Blackburn Building
The University of Sydney
NSW 2006 Australia

Tumour microenvironment, kinase inhibitors; Drug design; Inflammation

Publications

Yeung, Y., McDonald, K., Grewal, T., Munoz, L. (2013), Interleukins in glioblastoma pathophysiology: implications for therapy. British Journal of Pharmacology. 168(3), 591-606. [Abstract]

Yeung, Y., Bryce, N., Adams, S., Braidy, N., Konayagi, M., McDonald, K., Teo, C., Guillemin, G., Grewal, T., Munoz, L. (2012), p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. Journal of Neuro-Oncology. 109, 35-44. [Abstract]

Munoz, L., Ramsay, E., Manetsch, M., Ge, Q., Peifer, C., Laufer, S., Ammit, A. (2010), Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. European journal of pharmacology. 635(1-3), 212-8. [Abstract]
Munoz, L., Selig, R., Yeung, Y., Peifer, C., Hauser, D., Laufer, S. (2010), Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase. Analytical Biochemistry. 401(1), 125-133. [Abstract]
Munoz, L., Ammit, A. (2010), Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology. 58(3), 561-8. [Abstract]